Innogen licenses Efsubaglutide Alfa rights to Arcera in global expansion
Innogen Pharmaceuticals has signed an exclusive licensing and commercialization agreement with Arcera Life Sciences for Efsubaglutide Alfa in selected markets across Africa, Eastern Europe, Latin America and the Middle East. The deal includes US$38 million in upfront and near-term milestone payments, including a non-refundable US$15 million upfront payment, with potential total value exceeding US$1 billion.
- Arcera gains exclusive Efsubaglutide Alfa rights in selected countries across four regions.
- Innogen will receive US$38 million in upfront and near-term milestone payments.
- The agreement's potential total value is over US$1 billion.
- Efsubaglutide Alfa is being developed for type 2 diabetes, obesity and related metabolic diseases.
Arcera receives rights across four regions
Under the agreement, Arcera will receive exclusive rights to develop and commercialize Efsubaglutide Alfa in selected countries within Africa, Eastern Europe, Latin America and the Middle East. Innogen will retain the relevant rights in the rest of the world.
In addition to the upfront and near-term milestone payments, Innogen is eligible for sales milestone payments and tiered royalties of up to double-digit percentage rates based on aggregate annual net sales of the product in the licensed territory, according to the company.
Innogen said the collaboration is intended to combine its drug development capabilities with Arcera's international regulatory affairs, market access and commercialization strengths.
Efsubaglutide Alfa has diabetes and obesity development programs
Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an IgG Fc fragment. Innogen says the product has an average half-life of up to 280 hours across different studies.
According to Innogen, clinical studies found that monotherapy reduced HbA1c by 1.1 percentage points after four weeks, with a reduction of up to 2.2 percentage points at Week 24. The company also said the treatment may help protect pancreatic beta-cell function.
In the Phase IIb ENLIGHT study in Chinese adults with overweight or obesity, participants receiving 20 mg once weekly for 18 weeks achieved an average body-weight reduction of 10.6% and a waist-circumference reduction of approximately 8.9 cm. The group receiving 20 mg once every two weeks achieved an average body-weight reduction of 9.7%.
Innogen reported that the study observed improvements in body composition, including a muscle-to-fat ratio increase of up to 45.3% from baseline with once-weekly dosing. Liver fat content was reduced by up to 51.8% with that dosing schedule. The company said gastrointestinal adverse events were low relative to other GLP-1 receptor agonists based on cross-trial comparisons, and that no participants discontinued treatment because of adverse events during the 18-week treatment period.
The deal extends Innogen's international strategy
Innogen has completed a Phase II clinical trial in adults with overweight or obesity in Australia, evaluating once-monthly dosing. The company said the study generated further clinical evidence to support future global registration and commercialization.
Efsubaglutide Alfa has been approved for treating type 2 diabetes in mainland China and Macao, China, and is included in China's National Reimbursement Drug List (2025 Version), according to Innogen. The company said its manufacturing facilities have obtained PIC/S GMP certification.
“We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen's international expansion,” Innogen Founder, Chairman and Chief Executive Officer Dr. Qinghua Wang said.
Arcera Chief Executive Officer Isabel Afonso said the agreement “accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio.” Arcera is headquartered in Abu Dhabi, United Arab Emirates, and the company says it brings medicines to patients in over 100 countries.
For Innogen, the agreement creates a partner for development and commercialization in selected international territories while leaving rights elsewhere with the company. For patients in those territories, the collaboration could support access to Efsubaglutide Alfa as its development and regulatory work advances, although the announcement does not provide market launch dates.

